Trimurthi Limited, formerly Trimurthi Drugs & Pharmaceuticals Limited, is an India-based holding company, which is engaged in the supply of pharmaceutical products for wholesale and retail dealers. The Company is also engaged in interest income activities. Its segments include Pharma Business, Financial Activity, Investment Activity and Trading in Shares. The Company's services include distribution network for pharmaceutical products, retail pharmacy and marketing. The Company's products include T-SIF-O, POLYFLIC XT, Ulcizole-DSR, OXYMIN, Auscomin-S, Volivia Gold, Conplus, Oriflox, Treb-DSR, T-SIF 200, ACLO-P and LAMITAB, among others. The Company has its pharmacy retail outlets in Himayath Nagar and Inderbagh, Sultan Bazar in Hyderabad. The Company's subsidiaries include Trimurthi Pharmaceuticals India Private Limited and Trimurthi Foods Limited.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.